|
1.
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ma W, Wong CC, Tung EK, Wong CM and Ng IO:
RhoE is frequently down-regulated in hepatocellular carcinoma (HCC)
and suppresses HCC invasion through antagonizing the
Rho/Rho-kinase/myosin phosphatase target pathway. Hepatology.
57:152–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ho CL, Chen S, Yeung DW and Cheng TK:
Dual-tracer PET/CT imaging in evaluation of metastatic
hepatocellular carcinoma. J Nucl Med. 48:902–909. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Natsuizaka M, Omura T, Akaike T, et al:
Clinical features of hepatocellular carcinoma with extrahepatic
metastases. J Gastroenterol Hepatol. 20:1781–1787. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Xiang ZL, Zeng ZC, Tang ZY, et al:
Chemokine receptor CXCR4 expression in hepatocellular carcinoma
patients increases the risk of bone metastases and poor survival.
BMC Cancer. 9:1762009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1889. Cancer Metastasis Rev.
8:98–101. 1989.PubMed/NCBI
|
|
7.
|
Chung LW, Baseman A, Assikis V and Zhau
HE: Molecular insights into prostate cancer progression: the
missing link of tumor microenvironment. J Urol. 173:10–20. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Chackal-Roy M, Niemeyer C, Moore M and
Zetter BR: Stimulation of human prostatic carcinoma cell growth by
factors present in human bone marrow. J Clin Invest. 84:43–50.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Klopp AH, Gupta A, Spaeth E, Andreeff M
and Marini F III: Concise review: Dissecting a discrepancy in the
literature: do mesenchymal stem cells support or suppress tumor
growth? Stem Cells. 29:11–19. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Maestroni GJ, Hertens E and Galli P:
Factor(s) from nonmacrophage bone marrow stromal cells inhibit
Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life
Sci. 55:663–667. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kucerova L, Matuskova M, Hlubinova K,
Altanerova V and Altaner C: Tumor cell behaviour modulation by
mesenchymal stromal cells. Mol Cancer. 9:1292010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Karnoub AE, Dash AB, Vo AP, et al:
Mesenchymal stem cells within tumour stroma promote breast cancer
metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Lin JT, Wang JY, Chen MK, et al: Colon
cancer mesenchymal stem cells modulate the tumorigenicity of colon
cancer through interleukin 6. Exp Cell Res. 319:2216–2229. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Khakoo AY, Pati S, Anderson SA, et al:
Human mesenchymal stem cells exert potent antitumorigenic effects
in a model of Kaposi’s sarcoma. J Exp Med. 203:1235–1247.
2006.PubMed/NCBI
|
|
15.
|
Zhang C, Soori M, Miles FL, et al:
Paracrine factors produced by bone marrow stromal cells induce
apoptosis and neuroendocrine differentiation in prostate cancer
cells. Prostate. 71:157–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hernanda PY, Pedroza-Gonzalez A, van der
Laan LJ, et al: Tumor promotion through the mesenchymal stem cell
compartment in human hepatocellular carcinoma. Carcinogenesis.
34:2330–2340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Mizuguchi T, Hui T, Palm K, et al:
Enhanced proliferation and differentiation of rat hepatocytes
cultured with bone marrow stromal cells. J Cell Physiol.
189:106–119. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Jing Y, Han Z, Liu Y, et al: Mesenchymal
stem cells in inflammation microenvironment accelerates
hepatocellular carcinoma metastasis by inducing
epithelial-mesenchymal transition. PLoS One. 7:e432722012.
View Article : Google Scholar
|
|
19.
|
Li GC, Ye QH, Dong QZ, Ren N, Jia HL and
Qin LX: Mesenchymal stem cells seldomly fuse with hepatocellular
carcinoma cells and are mainly distributed in the tumor stroma in
mouse models. Oncol Rep. 29:713–719. 2013.PubMed/NCBI
|
|
20.
|
Li GC, Ye QH, Xue YH, et al: Human
mesenchymal stem cells inhibit metastasis of a hepatocellular
carcinoma model using the MHCC97-H cell line. Cancer Sci.
101:2546–2553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Niess H, Bao Q, Conrad C, et al: Selective
targeting of genetically engineered mesenchymal stem cells to tumor
stroma microenvironments using tissue-specific suicide gene
expression suppresses growth of hepatocellular carcinoma. Ann Surg.
254:767–775. 2011. View Article : Google Scholar
|
|
22.
|
Qiao L, Xu Z, Zhao T, et al: Suppression
of tumorigenesis by human mesenchymal stem cells in a hepatoma
model. Cell Res. 18:500–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ho IA, Toh HC, Ng WH, et al: Human bone
marrow-derived mesenchymal stem cells suppress human glioma growth
through inhibition of angiogenesis. Stem Cells. 31:146–155. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Sahin H, Trautwein C and Wasmuth HE:
Functional role of chemokines in liver disease models. Nat Rev
Gastroenterol Hepatol. 7:682–690. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Makinoshima H and Dezawa M: Pancreatic
cancer cells activate CCL5 expression in mesenchymal stromal cells
through the insulin-like growth factor-I pathway. FEBS Lett.
583:3697–3703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Luther SA and Cyster JG: Chemokines as
regulators of T cell differentiation. Nat Immunol. 2:102–107. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Charni F, Friand V, Haddad O, et al:
Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced
migration and invasion of human hepatoma cells. Biochim Biophys
Acta. 1790:1314–1326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Sutton A, Friand V, Papy-Garcia D, et al:
Glycosaminoglycans and their synthetic mimetics inhibit
RANTES-induced migration and invasion of human hepatoma cells. Mol
Cancer Ther. 6:2948–2958. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Liou JM, Lin JT, Huang SP, et al:
RANTES-403 polymorphism is associated with reduced risk of gastric
cancer in women. J Gastroenterol. 43:115–123. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kondo T, Ito F, Nakazawa H, Horita S,
Osaka Y and Toma H: High expression of chemokine gene as a
favorable prognostic factor in renal cell carcinoma. J Urol.
171:2171–2175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Honczarenko M, Le Y, Swierkowski M, Ghiran
I, Glodek AM and Silberstein LE: Human bone marrow stromal cells
express a distinct set of biologically functional chemokine
receptors. Stem Cells. 24:1030–1041. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Tyner JW, Uchida O, Kajiwara N, et al:
CCL5-CCR5 interaction provides antiapoptotic signals for macrophage
survival during viral infection. Nat Med. 11:1180–1187. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Bao M, Chen Z, Xu Y, et al: Sphingosine
kinase 1 promotes tumour cell migration and invasion via the
S1P/EDG1 axis in hepatocellular carcinoma. Liver Int. 32:331–338.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Palagyi A, Neveling K, Plinninger U, et
al: Genetic inactivation of the Fanconi anemia gene FANCC
identified in the hepatocellular carcinoma cell line HuH-7 confers
sensitivity towards DNA-interstrand crosslinking agents. Mol
Cancer. 9:1272010. View Article : Google Scholar
|
|
35.
|
Shi F, Shi M, Zeng Z, et al: PD-1 and
PD-L1 upregulation promotes CD8(+) T-cell apoptosis and
postoperative recurrence in hepatocellular carcinoma patients. Int
J Cancer. 128:887–896. 2011.
|
|
36.
|
Chen J, Liu WB, Jia WD, et al:
Overexpression of mortalin in hepatocellular carcinoma and its
relationship with angiogenesis and epithelial to mesenchymal
transition. Int J Oncol. 44:247–255. 2014.PubMed/NCBI
|
|
37.
|
Montella L, Addeo R, Palmieri G, et al:
Zoledronic acid in the treatment of bone metastases by
hepatocellular carcinoma: a case series. Cancer Chemother
Pharmacol. 65:1137–1143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Crawford BA, Kam C, Pavlovic J, et al:
Zoledronic acid prevents bone loss after liver transplantation: a
randomized, double-blind, placebo-controlled trial. Ann Intern Med.
144:239–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Lu YR, Yuan Y, Wang XJ, et al: The growth
inhibitory effect of mesenchymal stem cells on tumor cells in vitro
and in vivo. Cancer Biol Ther. 7:245–251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Wang SW, Wu HH, Liu SC, et al: CCL5 and
CCR5 interaction promotes cell motility in human osteosarcoma. PLoS
One. 7:e351012012. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Cambien B, Richard-Fiardo P, Karimdjee BF,
et al: CCL5 neutralization restricts cancer growth and potentiates
the targeting of PDGFRβ in colorectal carcinoma. PLoS One.
6:e288422011.PubMed/NCBI
|
|
42.
|
Vaday GG, Peehl DM, Kadam PA and Lawrence
DM: Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
Prostate. 66:124–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Gallo M, De Luca A, Lamura L and Normanno
N: Zoledronic acid blocks the interaction between mesenchymal stem
cells and breast cancer cells: implications for adjuvant therapy of
breast cancer. Ann Oncol. 23:597–604. 2012. View Article : Google Scholar
|
|
44.
|
Long H, Xie R, Xiang T, et al: Autocrine
CCL5 signaling promotes invasion and migration of CD133+
ovarian cancer stem-like cells via NF-κB-mediated MMP-9
upregulation. Stem Cells. 30:2309–2319. 2012.
|
|
45.
|
Barashi N, Weiss ID, Wald O, et al:
Inflammation-induced hepatocellular carcinoma is dependent on CCR5
in mice. Hepatology. 58:1021–1030. 2013. View Article : Google Scholar
|
|
46.
|
Orimo A, Gupta PB, Sgroi DC, et al:
Stromal fibroblasts present in invasive human breast carcinomas
promote tumor growth and angiogenesis through elevated SDF-1/CXCL12
secretion. Cell. 121:335–348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Mo W, Chen J, Patel A, et al: CXCR4/CXCL12
mediate autocrine cell-cycle progression in NF1-associated
malignant peripheral nerve sheath tumors. Cell. 152:1077–1090.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Liu H, Pan Z, Li A, et al: Roles of
chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in
metastasis of hepatocellular carcinoma cells. Cell Mol Immunol.
5:373–378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Li X, Yang Z, Song W, et al:
Overexpression of Bmi-1 contributes to the invasion and metastasis
of hepatocellular carcinoma by increasing the expression of matrix
metalloproteinase (MMP)-2, MMP-9 and vascular endothelial growth
factor via the PTEM/PI3K/Akt pathway. Int J Oncol. 43:793–802.
2013.PubMed/NCBI
|
|
50.
|
Suthiphongchai T, Promyart P, Virochrut S,
Tohtong R and Wilairat P: Involvement of ERK1/2 in invasiveness and
metastatic development of rat prostatic adenocarcinoma. Oncol Res.
13:253–259. 2003.PubMed/NCBI
|
|
51.
|
Diaz-Gil JJ, Garcia-Monzon C, Rua C, et
al: The anti-fibrotic effect of liver growth factor is associated
with decreased intrahepatic levels of matrix metalloproteinases 2
and 9 and transforming growth factor beta 1 in bile ductligated
rats. Histol Histopathol. 23:583–591. 2008.PubMed/NCBI
|
|
52.
|
Roomi MW, Kalinovsky T, Rath M and
Niedzwiecki A: In vitro modulation of MMP-2 and MMP-9 in
pediatric human sarcoma cell lines by cytokines, inducers and
inhibitors. Int J Oncol. 44:27–34. 2014.
|
|
53.
|
Xiang ZL, Zeng ZC, Fan J, et al: Gene
expression profiling of fixed tissues identified hypoxia-inducible
factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of
lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res.
17:5463–5472. 2011.PubMed/NCBI
|
|
54.
|
Wang YH, Dong YY, Wang WM, et al: Vascular
endothelial cells facilitated HCC invasion and metastasis through
the Akt and NF-κB pathways induced by paracrine cytokines. J Exp
Clin Cancer Res. 32:512013.PubMed/NCBI
|
|
55.
|
Gao J, Ding F, Liu Q and Yao Y: Knockdown
of MACC1 expression suppressed hepatocellular carcinoma cell
migration and invasion and inhibited expression of MMP2 and MMP9.
Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
